137 related articles for article (PubMed ID: 35422443)
1. Cost Effectiveness of
Rosen J; Ceccon G; Bauer EK; Werner JM; Tscherpel C; Dunkl V; Rapp M; Sabel M; Herrlinger U; Heinzel A; Schäfer N; Ruge M; Goldbrunner R; Stoffels G; Kabbasch C; Fink GR; Langen KJ; Galldiks N
J Nucl Med; 2022 Nov; 63(11):1677-1682. PubMed ID: 35422443
[TBL] [Abstract][Full Text] [Related]
2. MRI and
Rosen J; Werner JM; Ceccon GS; Rosen EK; Wollring MM; Stetter I; Lohmann P; Mottaghy FM; Fink GR; Langen KJ; Galldiks N
J Nucl Med; 2024 Jun; 65(6):838-844. PubMed ID: 38664020
[TBL] [Abstract][Full Text] [Related]
3. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
Heinzel A; Müller D; Langen KJ; Blaum M; Verburg FA; Mottaghy FM; Galldiks N
J Nucl Med; 2013 Aug; 54(8):1217-22. PubMed ID: 23785172
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas.
Heinzel A; Stock S; Langen KJ; Müller D
Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1089-96. PubMed ID: 22419257
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of [
Baguet T; Verhoeven J; De Vos F; Goethals I
Front Oncol; 2019; 9():814. PubMed ID: 31555584
[No Abstract] [Full Text] [Related]
6. O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis.
Heinzel A; Müller D; Yekta-Michael SS; Ceccon G; Langen KJ; Mottaghy FM; Wiesmann M; Kocher M; Hattingen E; Galldiks N
Neuro Oncol; 2017 Sep; 19(9):1271-1278. PubMed ID: 28204572
[TBL] [Abstract][Full Text] [Related]
7. Early Treatment Response Assessment Using
Ceccon G; Lohmann P; Werner JM; Tscherpel C; Dunkl V; Stoffels G; Rosen J; Rapp M; Sabel M; Herrlinger U; Schäfer N; Shah NJ; Fink GR; Langen KJ; Galldiks N
J Nucl Med; 2021 Jul; 62(7):918-925. PubMed ID: 33158907
[TBL] [Abstract][Full Text] [Related]
8. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
9.
Suchorska B; Unterrainer M; Biczok A; Sosnova M; Forbrig R; Bartenstein P; Tonn JC; Albert NL; Kreth FW
J Neurooncol; 2018 Sep; 139(3):721-730. PubMed ID: 29948765
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
11. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
[TBL] [Abstract][Full Text] [Related]
12. Comparison of O-(2-
Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
World Neurosurg; 2018 May; 113():e727-e737. PubMed ID: 29510293
[TBL] [Abstract][Full Text] [Related]
13. Comparison of [
Shymanskaya A; Worthoff WA; Stoffels G; Lindemeyer J; Neumaier B; Lohmann P; Galldiks N; Langen KJ; Shah NJ
Mol Imaging Biol; 2020 Feb; 22(1):198-207. PubMed ID: 30989437
[TBL] [Abstract][Full Text] [Related]
14. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
[TBL] [Abstract][Full Text] [Related]
15. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
[TBL] [Abstract][Full Text] [Related]
16. Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.
Wollring MM; Werner JM; Bauer EK; Tscherpel C; Ceccon GS; Lohmann P; Stoffels G; Kabbasch C; Goldbrunner R; Fink GR; Langen KJ; Galldiks N
Neuro Oncol; 2023 May; 25(5):984-994. PubMed ID: 36215231
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.
Floeth FW; Pauleit D; Sabel M; Stoffels G; Reifenberger G; Riemenschneider MJ; Jansen P; Coenen HH; Steiger HJ; Langen KJ
J Nucl Med; 2007 Apr; 48(4):519-27. PubMed ID: 17401087
[TBL] [Abstract][Full Text] [Related]
18. Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic.
Hutterer M; Ebner Y; Riemenschneider MJ; Willuweit A; McCoy M; Egger B; Schröder M; Wendl C; Hellwig D; Grosse J; Menhart K; Proescholdt M; Fritsch B; Urbach H; Stockhammer G; Roelcke U; Galldiks N; Meyer PT; Langen KJ; Hau P; Trinka E
J Nucl Med; 2017 Jan; 58(1):129-137. PubMed ID: 27469356
[TBL] [Abstract][Full Text] [Related]
19. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
Galldiks N; Dunkl V; Ceccon G; Tscherpel C; Stoffels G; Law I; Henriksen OM; Muhic A; Poulsen HS; Steger J; Bauer EK; Lohmann P; Schmidt M; Shah NJ; Fink GR; Langen KJ
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2377-2386. PubMed ID: 29982845
[TBL] [Abstract][Full Text] [Related]
20. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
